Pharming Group N.V. today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).

In deze webinar wordt Pharming Group CEO Sijmen de Vries geïnterviewd door Lifespring’s Leon Melens over de recente Investor tour die Pharming organiseerde in 2018, de positieve studieresultaten van eerste door onderzoekers geïnitieerde studie met rhC1INH in contrast-geïnduceerde nefropathie (nierschade door gebruik van contrastvloeistof) en de financiële resultaten van het derde kwartaal.

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.

Pharming Group N.V. announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.

Pharming Group N.V. announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the supplemental Biologics License Application (sBLA) for RUCONEST® [C1 Esterase Inhibitor (recombinant)] to expand the current indication to include prophylaxis in patients with hereditary angioedema (HAE).

Pharming Group N.V. today announced that it has issued a total of 6,240,000 new shares following exercise of warrants representing a total of 6,240,000 shares.

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2018.

Pharming Group N.V. announces the agenda for its Capital Markets Briefing to be held from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2018.